Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

Shares of Blueprint Medicines Corp (NASDAQ:BPMC) surged 26.5% following the announcement that the biopharmaceutical company will be acquired by Sanofi (NASDAQ:SNY) in a deal valued at approximately $9 ...

Shares of Blueprint Medicines Corp. (NASDAQ:BPMC) soared 26.5% after Sanofi (NASDAQ:SNY) revealed plans to acquire the ...

U.S. stock futures are pointing lower as investors review comments from China that accused the U.S. of undermining the recent ...

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

Sanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases.

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Blueprint Medicines Corporation to Sanofi is fair to Blueprint shareholders. Under the terms of the proposed ...

RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, ...

S&P 500 E-Mini futures (ESM25) are down -0.57%, andJune Nasdaq 100 E-Mini futures (NQM25) are down -0.69% this ...

Global healthcare company Sanofi, headquartered in Paris, France, is announcing another pricey purchase in the U.S.